This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RXi Pharmaceuticals Announces Initiation Of First Clinical Trial

RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology. RXI-109 has been shown to effectively silence a key regulator of scarring, connective tissue growth factor (CTGF), in vitro in cell culture and in vivo in rodent skin models. After completion of the necessary toxicological studies and clearance of their IND submission by the US Food and Drug Administration, they have now successfully dosed their first subject in a dose escalation study.

"This is an exciting time for RXi Pharmaceuticals, and for RNAi technology in general," said Pamela Pavco, Chief Development Officer for the company. "After an intense period of preparation, we are happy to announce the achievement of this significant milestone by RXi." She added that "Thanks to the potential of our proprietary self-delivering technology, we believe that RXI-109 will provide a highly selective and efficacious solution to an important unmet medical need. RXI-109 is designed to reduce or prevent skin scarring following trauma or surgery and is intended to reduce disfiguring hypertrophic scarring and keloids." RXi’s Phase 1 clinical trial is a dose escalation study designed to evaluate safety and tolerability of RXI-109 in humans and may provide preliminary evidence of the reduction of surgical scars.

About RXI-109

RXi Pharmaceuticals first clinical program centers around RXI-109, a self-delivering RNAi compound (sd-rxRNA®) developed by RXi for the reduction of dermal scarring in planned surgeries. RXI-109 is designed to reduce the expression of CTGF (connective tissue growth factor), a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. The first clinical trial of RXI-109, initiated in June 2012, will evaluate the safety and tolerability of several dose levels of RXI-109 in humans and may provide preliminary evidence of surgical scar reduction. As there are currently no FDA-approved drugs to prevent scar formation, a therapeutic of this type could have great benefit for trauma and surgical patients (especially relating to raised or hypertrophic scarring), as a treatment during the surgical revision of existing unsatisfactory scars, and in the treatment, removal and inhibition of keloids (scars which extend beyond the original skin injury).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs